Source: Cultivated X (October 12, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- n!Biomachines incorporated nBiomachines USA to provide sales and support for its real-time biosensors.
- The company says its multi-channel biosensor system continuously monitors cell culture and fermentation without manual sampling or physical probes.
- n!Biomachines has not disclosed the US location, staffing levels, or timeline for planned GMP manufacturing.
Canadian bioprocessing equipment maker n!Biomachines has incorporated nBiomachines USA, a subsidiary intended to provide local sales and customer support for the company's real-time biosensors. Founder and CEO Hamid Noori said the company ultimately plans to establish Good Manufacturing Practice, or GMP, production in the United States. The move puts a local commercial and support structure around sensors designed to continuously track important molecules during fermentation and cell culture. For manufacturers using living cells to make food ingredients, proteins, or biologic medicines, continuous measurement could reduce reliance on manual sampling.
A US base for biosensor customers
n!Biomachines, based in Burlington, Ontario, previously operated as The Cultivated B Canada before adopting its current name. Its parent company is German biotechnology business The Cultivated B, where Noori also serves as CEO.
Noori announced the US incorporation on LinkedIn, describing a phased plan for the new entity. “We have incorporated nBiomachines USA to serve our customers deploying our real-time biosensors, with sales, support and eventually GMP-manufacturing based locally.”
The company has not identified the subsidiary's US location, staffing plans, or a date for beginning GMP manufacturing. GMP refers to formal production standards used for pharmaceuticals and other regulated products, where manufacturers need consistent processes and documented quality controls.
Measuring a bioprocess as it runs
Fermentation and cell culture are biological production processes: microorganisms or cells grow in a controlled vessel and make a desired product. They are often monitored by drawing samples from the vessel, then testing those samples separately. n!Biomachines says its multi-channel system instead follows the process continuously without manual sampling or physical probes.
Think of the system as a dashboard for a bioreactor, the vessel where cells or microbes grow. Rather than waiting for a periodic check, the company says its biosensors can monitor chemicals that reveal whether a culture has enough nutrients and is accumulating metabolic byproducts.
The Cultivated B introduced the artificial intelligence-driven sensor system in February 2025. It said the platform detects molecules including glucose, amino acids, and lactic acid at concentrations below the picomolar level. Glucose and amino acids can serve as nutrients for growing cells, while lactic acid can indicate changes in a culture's metabolism.
Where the platform fits
n!Biomachines has identified fermentation-based food production, alternative proteins, biologics, and waste upcycling as potential uses for the sensor platform. Those sectors all depend on maintaining stable biological processes, often at larger scale than laboratory experiments.
The company also makes modular bioreactors, including the AUXO V system that it presented with Siemens at Hannover Messe in Germany. Its biosensor business therefore sits alongside equipment for running cell-culture and fermentation processes, rather than operating solely as a standalone analytical product.
Why This Matters
Continuous biosensing addresses a practical bottleneck in biomanufacturing: biological cultures can change between manual measurements. A platform that tracks multiple target molecules in real time could give process operators a closer view of nutrient use and metabolite buildup while production is underway.
The new subsidiary signals that n!Biomachines is building a US-facing sales and support operation around that platform, with future regulated manufacturing stated as an objective. The next milestones will be more concrete details on the US operation and whether the company moves from plans for GMP production to an operating manufacturing capability.
Topics: Biosensors · Diabetes & metabolism
Start here: Biosensors explained